Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Regional Lymph Node Macroscopic Metastases in Sarcoma Linked With Poor OS Outcomes

September 30th 2020

The presence of macroscopic metastases in regional lymph nodes is found to be related to poor survival outcomes in patients with sarcoma.

Avapritinib Approved in Europe for PDGFRA D842V–Mutant GIST

September 28th 2020

The European Commission has granted a conditional marketing authorization to avapritinib for single agent use in adult patients with unresectable or metastatic gastrointestinal stromal tumors that harbor a PDGFRA D842V mutation.

Even in COVID-19 World, Children’s Oncology Group Tackles Unmet Needs in Sarcomas

September 28th 2020

R. Lor Randall, MD, highlights the innovative efforts by the COG, ongoing studies in sarcomas, and how the organization is adapting during a world with COVID-19.

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21st 2020

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

Pembrolizumab Prolongs PFS in Rare Sarcoma Subtypes

September 21st 2020

Pembrolizumab monotherapy prolonged progression-free survival in selected rare sarcoma subtypes, supporting the immune checkpoint inhibitor’s ability to improve outcomes across histotypes.

Regorafenib Showed Modest Activity in Ewing Sarcoma

September 20th 2020

Regorafenib extended progression-free survival at 24 weeks compared with placebo for patients with Ewing sarcoma in the phase 2 REGOBONE study. However, the oral multi-kinase inhibitor failed to meet the study’s primary endpoint of non-progression at 8 weeks.

Dr. Pautier on Remaining Challenges in Advanced Soft Tissue Sarcoma

September 11th 2020

Patricia Pautier, MD, discusses remaining challenges in treating patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Doxorubicin and Trabectedin Combo Impresses in Soft Tissue Sarcoma

September 8th 2020

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial, the importance of histologic stratification, and ongoing challenges in soft tissue sarcoma.

Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

September 8th 2020

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in uterine and soft tissue leiomyosarcoma.

Dr. Roland on Findings From a Phase 2 Study With Neoadjuvant Checkpoint Blockade in Sarcoma

September 1st 2020

Christina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Dr. Gronchi on the Toxicity Profile of Trabectedin Plus Radiotherapy in Sarcoma

August 31st 2020

Alessandro Gronchi, MD, discusses the toxicity profile of trabectedin and radiation therapy in patients with soft tissue sarcoma.

Chemotherapy Infrequently Used in High-Risk Sarcoma, Despite Proven Benefit

August 31st 2020

The overall use of chemotherapy in high-risk soft tissue sarcomas has been found to be significantly low.

Sarcoma Experts Elucidate on Combination Chemotherapy Regimens

August 31st 2020

In a special episode of OncLive® On Air, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, highlight research evaluating combination chemotherapy regimens in the evolving sarcoma treatment paradigm.

Dr. Weitzel on the Identification of Li-Fraumeni Syndrome

August 28th 2020

Jeffery Weitzel, MD, discusses the identification of Li-Fraumeni syndrome.

Dr. Serrano on the Rationale for the INVICTUS Trial in Advanced GIST

August 28th 2020

César Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Schwartz Hunts for Predictive Biomarkers in Soft Tissue Sarcoma

August 26th 2020

Gary K. Schwartz, MD, highlights research that is being done with regard to genomic signatures in sarcoma, challenges faced with immunotherapy, and where the field is headed.

Dr. Pautier on Doxorubicin Plus Trabectedin in Soft Tissue Sarcoma

August 24th 2020

Patricia Pautier, MD, discusses the toxicity profile of doxorubicin with trabectedin in the phase 2 LMS-02 trial in patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Experts Spotlight Ongoing Efforts Evaluating Immunotherapy in Sarcoma

August 21st 2020

Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.

Dr. Abraham on Future Research in TGCT

August 21st 2020

John A. Abraham, MD, FACS, discusses future research efforts in tenosynovial giant cell tumor.

Randall Underscores the Need for Multidisciplinary Management of Desmoid Fibromatosis

August 21st 2020

R. Lor Randall, MD, FACS, discusses the evolving management of desmoid fibromatosis, shares advice on the factors that go into deciding when to treat this disease, and stresses the importance of having a multidisciplinary team involved in the care of these patients.